Comparison of anticancer drug coverage decisions in the United States and United Kingdom: Does the evidence support the rhetoric?

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3234-3238

  Mason, Anne ^a   Drummond, Michael ^a   Ramsey, Scott ^a   Campbell, Jonathan ^a   Raisch, Dennis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG APPROVAL; GOVERNMENT; HUMAN; INTERPERSONAL COMMUNICATION; LICENSING; MEDICAID; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; PUBLIC HEALTH; REIMBURSEMENT; TIME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG APPROVAL; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICARE; NATIONAL HEALTH PROGRAMS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954707651     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.2758     Document Type: Article

References (22)

1. Sullivan SD, Watkins J, Sweet B, et al: Health technology assessment in health-care decisions in the United States. Value Health 12:S39-S44, 2009 (suppl 2)
2. Fry RN, Avey SG, Sullivan SD: The Academy of Managed Care Pharmacy Format for Formulary Submissions: An evolving standard - a Foundation for Managed Care Pharmacy Task Force report. Value Health 6:505-521, 2003 (Pubitemid 37187712)
3. Watkins JB, Minshall ME, Sullivan SD: Application of economic analyses in U.S. managed care formulary decisions: A private payer's experience. J Manag Care Pharm 12:726-735, 2006 (Pubitemid 47394434)
4. McGreal C: In the US things are getting nasty over NICE. BMJ 338:b2058, 2009
5. National Institute for Health and Clinical Excellence: Guide to the Methods of Technology Appraisal. London, United Kingdom, National Institute for Health and Clinical Excellence, 2008
6. Barham L: Single technology appraisals by NICE: Are they delivering faster guidance to the NHS? Pharmacoeconomics 26:1037-1043, 2008
7. National Institute for Health and Clinical Excellence: Guide to the Single Technology Appraisal (STA) Process. London, United Kingdom, National Institute for Health and Clinical Excellence, 2006
8. Neumann PJ, Rosen AB, Weinstein MC: Medicare and cost-effectiveness analysis. N Engl J Med 353:1516-1522, 2005 (Pubitemid 41400929)
9. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
10. Abernethy AP, Raman G, Balk EM, et al: Systematic review: Reliability of compendia methods for off-label oncology indications. Ann Intern Med 150:336-343, 2009
11. House of Commons Health Committee: National Institute for Health and Clinical Excellence. London, United Kingdom, The Stationery Office Limited, 2008
12. Department of Veterans Affairs: VHA Formulary Management Process. VHA HANDBOOK 1108.08. Washington, DC, Veterans Health Administration, 2009, pp 1-29
13. StatsDirect: StatsDirect Statistical Software (version 2.6.6). Cheshire, United Kingdom, StatsDirect Ltd, 2008
14. Mason AR, Drummond MF: Public funding of new cancer drugs: Is NICE getting nastier? Eur J Cancer 45:1188-1192, 2009
15. Lee TH, Emanuel EJ: Tier 4 drugs and the fraying of the social compact. N Engl J Med 359:333-335, 2008
16. Richards M: Improving access to medicines for NHS patients. A report for the Secretary of State for Health by Professor Mike Richards CBE, November 2008. London, United Kingdom, Department of Health, 2008
17. Stacey D, Samant R, Bennett C: Decision making in oncology: A review of patient decision aids to support patient participation. CA Cancer J Clin 58:293-304, 2008
18. Neumann PJ: Why don't Americans use cost-effectiveness analysis? Am J Manag Care 10:308-312, 2004
19. Darzi A: High quality care for all: NHS next stage review final report. London, United Kingdom, Department of Health, 2008
20. Tunis SR, Pearson SD: Coverage options for promising technologies: Medicare's 'coverage with evidence development.' Health Aff 25:1218-1230, 2006
21. Oberlander J: Picking the right poison: Options for funding health care reform. N Engl J Med 360:2045-2048, 2009
22. Ubel PA, Hirth RA, Chernew ME, et al: What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163:1637-1641, 2003